

DOCTRC

DENTAL, ORAL, & CRANIOFACIAL TISSUE
REGENERATION CONSORTIUM
www.doctrc.org

DOCTRC presents the
DOCTRC Innovator Networking Series

TAKE YOUR RESEARCH FROM BENCH TO BEDSIDE

November
17
2023

Learn about the transition from basic discovery to translational research.



REGISTER NOW!

Location: Online via Zoom

Attendees **must** register before November 16.
Click [here](#) to register.



November 17, 2023



9-10am PT | 12-1pm ET

THE SPEAKERS



Gary D. Hammer, MD, PhD

Professor, University of Michigan
Director, Endocrine Oncology Program
in Rogel Cancer Center



Charles Hart, PhD

Executive Director,
UCSF Innovation Ventures
Catalyst Program

For more information, please contact:



VyVy Nguyen (vyvyn@usc.edu)

Mutsumi Yoshida (yoshidam@umich.edu)

DOCTRC

DENTAL, ORAL, & CRANIOFACIAL TISSUE
REGENERATION CONSORTIUM

www.doctrc.org

DOCTRC Presents the 3rd Installment of
the DOCTRC Innovator Networking Series

THE SPEAKERS



November 17, 2023



9-10am PT | 12-1pm ET



Gary D. Hammer, MD, PhD

Professor, University of Michigan
Director, Endocrine Oncology
Program in Rogel Cancer Center

Gary D. Hammer, M.D., Ph.D. is Professor in Departments of Internal Medicine (MEND), Cell & Developmental Biology, and Molecular & Integrative Physiology. He currently serves as Director of Endocrine Oncology Program in Rogel Cancer Center where he holds the Millie Schembechler Professorship in Adrenal Cancer. He is past Director of Center for Organogenesis: Stem Cells & Regenerative Medicine. He has brokered the recent renaissance of the current Michigan team of adrenal scientists that includes a who's who in the study of adrenal disease. He received the UofM Jerome Conn Award for Outstanding Research in Internal Medicine, the Endocrine Society Edwin B. Astwood Award for Outstanding Research and is a member of ASCI and AAP. He has served in numerous leadership roles at UofM and in the public and private sectors including recent tenure on Board of Scientific Advisors for NCI. He is the editor of four textbooks including Pathophysiology of Disease: An Introduction to Clinical Medicine (McGraw Hill), and the Adrenal Section Editor for Degroot's Endocrinology (Elsevier). He has served in numerous capacities for the world's largest endocrine organization, the Endocrine Society including his most recent role as President of the Society (2020-2021). An Advisor to the Congressional H.E.L.P. committee - he co-authored the 21st Century Cancer ALERT (Access to Life-Saving Early detection, Research and Treatment) Act" introduced in Congress in 2009. He has been catalyst for the formation of two international cooperative groups, most recently the A5 (American Australian Asian Adrenal Alliance) that leverages collaboration to secure projects from Pharma and funding agencies across the spectrum of adrenal diseases. He is a co-founder of two companies - MILLENDO and SLING THERAPEUTICS that focus on rare endocrine diseases.



Charles Hart, PhD

Executive Director,
UCSF Innovation Ventures
Catalyst Program

Charles Hart is the director of the Catalyst program. From 2004 to 2017 he was at Threshold Pharmaceuticals and responsible for both in vitro and in vivo preclinical translational studies. He was also project leader for the global clinical development program for the hypoxia-targeted anticancer drug evofosfamide (TH-302), a partnership with Merck KGaA. Prior to joining Threshold, Charles was Senior Director of Biology at Galileo Pharmaceuticals (2001 to 2004), Director of Drug Discovery at Signature Bioscience (2000 to 2001), and a Research Unit Director at Affymax (1990 to 2000). Charles received his AB in cell biology from the University of California, Berkeley in 1977, an MS in developmental biology from Stanford University in 1980, a PhD in molecular biology and genetics from Yale University in 1987, and completed a postdoctoral fellowship at the University of Strasbourg, France in 1990.

For more information, please contact:



VyVy Nguyen (vyvyn@usc.edu)

Mutsumi Yoshida (yoshidam@umich.edu)